HLS Therapeutics Inc. (OTCMKTS:HLTRF) Short Interest Update

HLS Therapeutics Inc. (OTCMKTS:HLTRF) was the target of a large increase in short interest in August. As of August 14th, there was short interest totaling 1,646 shares, an increase of 269.1% from the July 30th total of 446 shares. Based on an average trading volume of 2,461 shares, the days-to-cover ratio is currently 0.7 days.

Wall Street Analysts Forecast Growth

Separately, Raymond James Financial raised HLS Therapeutics from an “outperform” rating to a “strong-buy” rating in a report on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat, the company has an average rating of “Strong Buy”.

HLS Therapeutics Trading Up 1.2%

Shares of HLTRF opened at $2.68 on Thursday. The stock has a 50 day moving average price of $2.97 and a 200 day moving average price of $3.17. HLS Therapeutics has a one year low of $2.65 and a one year high of $4.02.

About HLS Therapeutics

HLS Therapeutics is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription products for niche therapeutic markets. Headquartered in Mississauga, Ontario, the company builds its portfolio through strategic licensing agreements and in-house development, with an emphasis on therapies that address unmet needs in neurology and rare disorders.

The company’s marketed offering includes treatments for neurological conditions, most notably primary periodic paralysis, for which it commercializes dichlorphenamide (Keveyis) in North America.